Aeterna Zentaris (AEZS) +24% after final Phase 3 results for its AEZS-130 drug show that it's...

|By:, SA News Editor

Aeterna Zentaris (AEZS) +24% after final Phase 3 results for its AEZS-130 drug show that it's safe and effective in diagnosing adult growth hormone deficiency, which can cause diminished lean body mass, poor bone density, and psychological symptoms. (PR)